Journal
CRITICAL REVIEWS IN BIOTECHNOLOGY
Volume 41, Issue 1, Pages 121-153Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/07388551.2020.1830746
Keywords
Biosimilars; rheumatoid arthritis; bioprocessing costs; TNF; monoclonal antibodies
Categories
Funding
- Research England Connecting Capability Fund (CCF), THYME Project (Teesside, Hull and York-Mobilising Bioeconomy Knowledge Exchange) [ccf14-7167]
Ask authors/readers for more resources
Global healthcare systems are facing challenges in funding innovative treatment costs, particularly in the biosimilars market as patent expirations approach for well-known monoclonal antibodies. The development costs of biosimilars are significantly higher than generic equivalents due to therapeutic trials and manufacturing expenses, impacting efforts to lower prices for cancer and autoimmune disorder treatments. Academic and industry understanding of the complex costs and stages of biologics processing is crucial for navigating the evolving landscape of healthcare.
Healthcare systems worldwide are struggling to find ways to fund the cost of innovative treatments such as gene therapies, regenerative medicine, and monoclonal antibodies (mAbs). As the world's best known mAbs are close to facing patent expirations, the biosimilars market is poised to grow with the hope of bringing prices down for cancer treatment and autoimmune disorders, however, this has yet to be realized. The development costs of biosimilars are significantly higher than their generic equivalents due to therapeutic equivalence trials and higher manufacturing costs. It is imperative that academics and relevant companies understand the costs and stages associated with biologics processing. This article brings these costs to the forefront with a focus on biosimilars being developed for Rheumatoid Arthritis (RA). mAbs have remarkably changed the treatment landscape, establishing their superior efficacy over traditional small chemicals. Five blockbuster TNF alpha mAbs, considered as first line biologics against RA, are either at the end of their patent life or have already expired and manufacturers are seeking to capture a significant portion of that market. Although in principle, market-share should be available, withstanding that the challenges regarding the compliance and regulations are being resolved, particularly with regards to variation in the glycosylation patterns and challenges associated with manufacturing. Glycan variants can significantly affect the quality attributes requiring characterization throughout production. Successful penetration of biologics can drive down prices and this will be a welcome change for patients and the healthcare providers. Herein we review the biologic TNF alpha inhibitors, which are on the market, in development, and the challenges being faced by biosimilar manufacturers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available